NASDAQ:LNSR LENSAR (LNSR) Stock Price, News & Analysis → Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (From InvestorPlace) (Ad) Free LNSR Stock Alerts $3.83 +0.05 (+1.32%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$3.66▼$3.9650-Day Range$3.00▼$4.3552-Week Range$1.80▼$5.30Volume29,412 shsAverage Volume40,929 shsMarket Capitalization$43.66 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get LENSAR alerts: Email Address LENSAR MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside108.9% Upside$8.00 Price TargetShort InterestHealthy0.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector1479th out of 2,771 stocksSurgical & Medical Instruments Industry181st out of 300 stocks 3.5 Analyst's Opinion Consensus RatingLENSAR has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENSAR has only been the subject of 1 research reports in the past 90 days.Read more about LENSAR's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.74% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LENSAR has recently increased by 1.18%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLENSAR does not currently pay a dividend.Dividend GrowthLENSAR does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LNSR. Previous Next 3.2 News and Social Media Coverage News SentimentLENSAR has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for LENSAR this week, compared to 0 articles on an average week.Search Interest2 people have searched for LNSR on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LENSAR insiders have not sold or bought any company stock.Percentage Held by Insiders66.00% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENSAR's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of LENSAR is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENSAR is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENSAR has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about LENSAR's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceMillionaire investor and Republican donor makes surprising election predictionFind out who Louis believes is going to win the election... And why that will launch a second boom in AI stocksClick for his six specific AI stock in the crosshairs About LENSAR Stock (NASDAQ:LNSR)LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Read More LNSR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNSR Stock News HeadlinesMay 13 at 3:45 PM | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Q1 2024 Earnings Call TranscriptMay 13 at 10:44 AM | seekingalpha.comLENSAR, Inc. (LNSR) Q1 2024 Earnings Call TranscriptMay 12 at 7:42 PM | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Just Reported, And Analysts Assigned A US$8.00 Price TargetMay 11 at 12:02 PM | finance.yahoo.comLENSAR First Quarter 2024 Earnings: EPS Beats ExpectationsMay 9, 2024 | investorplace.comLNSR Stock Earnings: LENSAR Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comLENSAR Reports First Quarter 2024 Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comLENSAR (LNSR) to Release Earnings on ThursdayMay 2, 2024 | businesswire.comLENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024May 1, 2024 | businesswire.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 21, 2024 | morningstar.comLENSAR Inc Ordinary Shares LNSRApril 1, 2024 | businesswire.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2024 | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Just Reported Earnings, And Analysts Cut Their Target PriceMarch 5, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: 89bio (ETNB), UnitedHealth (UNH)March 5, 2024 | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | finance.yahoo.comLENSAR Full Year 2023 Earnings: EPS Beats ExpectationsMarch 4, 2024 | finance.yahoo.comLENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 1, 2024 | businesswire.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | businesswire.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | msn.comLENSAR Q4 2023 Earnings PreviewFebruary 28, 2024 | markets.businessinsider.comNavigating 6 Analyst Ratings For Viridian TherapeuticsFebruary 26, 2024 | businesswire.comLENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024February 26, 2024 | businesswire.comLENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024February 22, 2024 | benzinga.comLENSAR Stock (NASDAQ:LNSR), Short Interest ReportFebruary 7, 2024 | msn.comLENSAR Board Approves Executive Bonuses for 2023 PerformanceJanuary 25, 2024 | finance.yahoo.comLENSAR Decline Means Insider Profits Down To US$42kSee More Headlines Receive LNSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/14/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LNSR CUSIPN/A CIK1320350 Webwww.lensar.com Phone888-536-7271FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+108.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,380,000.00 Net Margins-27.57% Pretax Margin-27.57% Return on Equity-36.53% Return on Assets-17.67% Debt Debt-to-Equity RatioN/A Current Ratio4.06 Quick Ratio2.36 Sales & Book Value Annual Sales$42.16 million Price / Sales1.04 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book1.29Miscellaneous Outstanding Shares11,400,000Free Float3,875,000Market Cap$43.66 million OptionableOptionable Beta0.49 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Nicholas T. Curtis (Age 67)President, CEO & Director Comp: $974.29kMr. Thomas R. Staab II (Age 56)CPA, CFO & Secretary Comp: $612.55kMr. Alan B. Connaughton (Age 52)Chief Operating Officer Comp: $650.62kMs. Kendra W. Wong (Age 44)Principal Accounting Officer Key CompetitorsModular MedicalNASDAQ:MODDCo-DiagnosticsNASDAQ:CODXCarmellNASDAQ:CTCXSeaStar MedicalNASDAQ:ICURetractable TechnologiesNYSE:RVPView All CompetitorsInsidersGary M WinerBought 300 shares on 11/22/2023Total: $630.00 ($2.10/share)Gary M WinerBought 500 shares on 11/15/2023Total: $1,075.00 ($2.15/share)Gary M WinerBought 1,000 shares on 11/10/2023Total: $2,130.00 ($2.13/share)Gary M WinerBought 1,000 shares on 8/10/2023Total: $3,660.00 ($3.66/share)Aimee S WeisnerBought 16,647 shares on 5/22/2023Total: $45,779.25 ($2.75/share)View All Insider Transactions LNSR Stock Analysis - Frequently Asked Questions Should I buy or sell LENSAR stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LENSAR in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNSR shares. View LNSR analyst ratings or view top-rated stocks. What is LENSAR's stock price target for 2024? 1 Wall Street research analysts have issued 12 month price objectives for LENSAR's stock. Their LNSR share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 108.9% from the stock's current price. View analysts price targets for LNSR or view top-rated stocks among Wall Street analysts. How have LNSR shares performed in 2024? LENSAR's stock was trading at $3.51 at the beginning of the year. Since then, LNSR shares have increased by 9.1% and is now trading at $3.83. View the best growth stocks for 2024 here. When is LENSAR's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our LNSR earnings forecast. How were LENSAR's earnings last quarter? LENSAR, Inc. (NASDAQ:LNSR) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.19) EPS for the quarter. The company earned $10.59 million during the quarter. LENSAR had a negative net margin of 27.57% and a negative trailing twelve-month return on equity of 36.53%. How do I buy shares of LENSAR? Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LNSR) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressNo experience to confident trader, meet my student…Wealth Builders InstituteThe only AI company you should be looking atBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
